The UK and US have reached a significant bilateral deal that will preserve zero tariffs on UK pharmaceutical exports being sold in the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to raise funding on medicines through the NHS. This move secures that duties on these key exports will remain at nothing for a timeframe of three years.
This development is in response to earlier warnings to hike duties on patented pharmaceutical products, with figures floated up to one hundred percent.
"This agreement with the Britain bolsters the global environment for innovative medicines and establishes much-needed balance to transatlantic drug exports," an announcement noted.
Commercial Impact
Medicines are one of the the United Kingdom's biggest export categories to the US, which is clearly the biggest buyer for large companies like GSK and AstraZeneca.
Export figures show that in the 12 months to the end of the third quarter, the UK exported medicines valued at £11.1bn to the US. This figure represented nearly one-fifth of total UK exports in that span.
"This guarantee safeguards work, boosts funding and sets the stage for the UK to become a global hub for life sciences," a government official remarked.
Detailed UK Commitments
The pact involves several notable commitments from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to double total public funding on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to prevent overspending will be capped at fifteen percent. In the past, repayments exceeded 20%.
Broader Context
The pact follows a protracted tension between the sector and the ministers over spending levels and NHS adoption.
The disagreement were exacerbated by assertions that US patients were charged several times more for the equivalent treatments than patients in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been halted or abandoned, while major funding commitments have been announced toward US facilities.
A senior figure publicly accepted that the NHS had to spend more on medicines, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.
